+44 20 8123 2220
info@marketpublishers.com

Global Alzheimer Drugs Market (2022 Edition) – Analysis By Drug Class (Cholinergic, Memantine, Combined Drugs, Others), Distribution Channel, By Region, By Country: Market Insights, Pipeline and Forecast with Impact of Covid-19 (2022-2027)

https://marketpublishers.com/r/GCE8690AA056EN.html
Date: January 2022
Pages: 220
Price: US$ 2,400.00 (Single User License)
ID: GCE8690AA056EN

Abstracts

Executive Summary

According to Azoth Analytics research report, the Global Alzheimer Drugs Market was valued at USD 6537.0 Million in the year 2021.

Diabetes, obesity, heart diseases and high blood pressure (BP), in confluence with sedentary lifestyles, unhealthy dietary patterns and smoking, are some of the factors known to increase the chances of developing Alzheimer's disease. An increase in the prevalence of these ailments and lifestyle choices among the masses, coupled with the rising geriatric population, represents one of the key factors driving the market growth. Furthermore, the leading pharmaceutical companies are focusing on the development of drugs that prevent the disease and provide long-lasting improvements in cognitive functions.

In addition, the market growth is further supported by the expansion of telehealth services and the growing traction of online pharmacies. Telehealth can be defined as the remote delivery of clinical as well as non-clinical services through tele- and digital communication technologies. These platforms have enabled disease diagnosis and drug delivery in remote regions. Apart from this, various Alzheimer's drugs are presently under late-stage clinical trials, including Aducanumab and Solanezumab. The development of these drugs is anticipated to propel the market growth in the coming years.

Moreover, increasing prevalence of Alzheimer's disease is fueling the demand for Alzheimer’s drugs which in turn is driving the global Alzheimer’s drugs market. Also, rising R&D activities by pharmaceutical companies and research institutes for Alzheimers’ effective therapy is expected to boost the global Alzheimer’s drugs market.

Scope of the Report

The report presents the analysis of Alzheimer Drugs market for the historical period of 2017-2021 and the forecast period of 2022-2027

The report analyses the Alzheimer Drugs Market by value (USD Million)

The report analyses the Alzheimer Drugs Market by Drug Class (Cholinergic, Memantine, Combined drug, others).

The report analyses the Alzheimer Drugs Market by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

The Global Alzheimer Drugs Market has been analysed By Region (North America, Europe, Asia Pacific and LAMEA).

The Global Alzheimer Drugs Market has been analysed By Country (United States, Canada, Germany, United Kingdom, France, Italy, China, Japan, India and Australia)

The attractiveness of the market has been presented by region, by Drug Class and By Distribution Channel.

Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.

The report tracks competitive developments, strategies, mergers and acquisitions and new product development.

The companies analysed in the report include AbbVie Inc., F. Hoffman-La Roche, Ltd., Novartis AG, Biogen, Pfizer Inc., Eli Lilli and Company, Takeda Pharmaceutical Company Limited, Novo Nordisk, Daiichi Sankyo Company Ltd.,

+44 20 8123 2220
info@marketpublishers.com

Eisai Co. Ltd, NervGen Pharma.

Key Target Audience:

Alzheimer Drugs Manufacturers

Consulting and Advisory Firms

Government and Policy Makers

Regulatory Authorities

+44 20 8123 2220
info@marketpublishers.com

Contents

1. REPORT SCOPE AND METHODOLOGY

1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary

2. STRATEGIC RECOMMENDATIONS

3. ALZHEIMER DRUGS MARKET: PRODUCT OUTLOOK

4. GLOBAL ALZHEIMER DRUGS MARKET: SIZING AND FORECAST

4.1 Global Alzheimer Drugs Market Size, By Value, Year 2017-2027
4.2 Impact of COVID-19 on Global Alzheimer Drugs Market

5. GLOBAL ALZHEIMER DRUGS MARKET SEGMENTATION – BY DRUG CLASS, BY DISTRIBUTION CHANNEL

5.1 Competitive Scenario of Global Alzheimer Drugs Market: By Drug Class
  5.1.1 Cholinergic – Market Size and Forecast (2017-2027)
  5.1.2 Memantine – Market Size and Forecast (2017-2027)
  5.1.3 Combined drug – Market Size and Forecast (2017-2027)
  5.1.4 Others – Market Size and Forecast (2017-2027)
5.3 Competitive Scenario of Global Alzheimer Drugs Market: By Distribution Channel
  5.3.1 Hospitals Pharmacy– Market Size and Forecast (2017-2027)
  5.3.2 Retail Pharmacy - Market Size and Forecast (2017-2027)
  5.3.3 Online Pharmacy – Market Size and Forecast (2017-2027)

6. GLOBAL ALZHEIMER DRUGS MARKET: REGIONAL ANALYSIS

6.1 Competitive Scenario of Global Alzheimer Drugs Market : By Region

7. NORTH AMERICA ALZHEIMER DRUGS MARKET: AN ANALYSIS (2017-2027)

7.1 North America Alzheimer Drugs Market : Size and Forecast (2017-2027), By Value
7.2 North America Alzheimer Drugs Market – Prominent Companies
7.3 Market Segmentation By Drug Class (Cholinergic, Memantine, Combined drug and

Others)
7.4 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
7.5 North America Alzheimer Drugs Market: Country Analysis
7.6 Market Opportunity Chart of North America Alzheimer Drugs Market - By Country, By Value, 2026
7.7 Competitive Scenario of North America Alzheimer Drugs Market: By Country
7.8 United States Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
7.9 United States Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
7.10 Canada Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
7.11 Canada Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)

8. EUROPE ALZHEIMER DRUGS MARKET: AN ANALYSIS (2017-2027)

8.1 Europe Alzheimer Drugs Market : Size and Forecast (2017-2027), By Value
8.2 Europe Alzheimer Drugs Market – Prominent Companies
8.3 Market Segmentation By Drug Class (Cholinergic, Memantine, Combined drug and Others)
8.4 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
8.5 Europe Alzheimer Drugs Market: Country Analysis
8.6 Market Opportunity Chart of Europe Alzheimer Drugs Market - By Country, By Value, 2026
8.7 Competitive Scenario of Europe Alzheimer Drugs Market: By Country
8.8 Germany Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
8.9 Germany Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
8.10 United Kingdom Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
8.11 United Kingdom Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
8.12 France Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
8.13 France Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
8.14 Italy Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
8.15 Italy Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)

9. ASIA PACIFIC ALZHEIMER DRUGS MARKET: AN ANALYSIS (2017-2027)

9.1 Asia Pacific Alzheimer Drugs Market : Size and Forecast (2017-2027), By Value
9.2 Asia Pacific Alzheimer Drugs Market – Prominent Companies
9.3 Market Segmentation By Drug Class (Cholinergic, Memantine, Combined drug and Others)
9.4 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
9.5 Asia Pacific Alzheimer Drugs Market: Country Analysis
9.6 Market Opportunity Chart Asia Pacific Alzheimer Drugs Market - By Country, By Value, 2026
9.7 Competitive Scenario of Asia Pacific Alzheimer Drugs Market: By Country
9.8 China Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
9.9 China Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
9.10 Japan Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
9.11 Japan Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
9.12 India Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
9.13 India Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
9.14 Australia Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
9.15 Australia Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)

10. GLOBAL ALZHEIMER DRUGS MARKET DYNAMICS

10.1 Drivers
10.2 Restraints
10.3 Trends

11. MARKET ATTRACTIVENESS

11.1 Market Attractiveness Chart of Global Alzheimer Drugs Market - By Drug Class, 2026
11.2 Market Attractiveness Chart of Global Alzheimer Drugs Market - By Distribution Channel, 2026
11.3 Market Attractiveness Chart of Global Alzheimer Drugs Market - By Region, 2026

+44 20 8123 2220
info@marketpublishers.com

12. COMPETITIVE LANDSCAPE

12.1 Product Pipeline of Leading Alzheimer Drugs Companies
12.2 Market Share Analysis

13. COMPANY ANALYSIS

13.1 AbbVie Inc.,
13.2 F. Hoffman-La Roche, Ltd.
13.3 Novartis AG
13.4 Biogen
13.5 Pfizer Inc.,
13.6 Eli Lilli and Company
13.7 Takeda Pharmaceutical Company Limited
13.8 Novo Nordisk
13.9 Daiichi Sankyo Company Ltd.
13.10 Eisai Co. Ltd
13.11 NervGen Pharma

14. ABOUT US

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Global Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
Global Number of People With Dementia, in Million, in Low, Middle and High In come Countries, 2015-2020
World's leading causes of death (in millions), 2019
World Population 65 Years & Above (% of Total), 2015-2019
Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Global Alzheimer - Number of Drugs by Phase, In Percentage, 2020
Global Alzheimer Drugs Market- By Drug Class Market Share, 2021 & 2027
Global Alzheimer Drugs Market- By Cholinergic, By Value (USD Million), 2017-2027
Global Alzheimer Drugs Market- By Memantine, By Value (USD Million), 2017-2027
Global Alzheimer Drugs Market- By Combined drug, By Value (USD Million), 2017-2027
Global Alzheimer Drugs Market- By Others, By Value (USD Million), 2017-2027
Global Alzheimer Drugs Market- By Distribution Channel Market Share, 2021 & 2027
Global Alzheimer Drugs Market- By Hospital Pharmacy, By Value (USD Million), 2017-2027
Global Alzheimer Drugs Market- By Retail Pharmacy, By Value (USD Million), 2017-2027
Global Alzheimer Drugs Market- By Online Pharmacy, By Value (USD Million), 2017-2027
Global Alzheimer Drugs Market- By Region Market Share, 2021 & 2027
North America Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
North America Population ages 65 and above (% of total Population), 2016-2020
United States lifetime risk for Alzheimer's dementia at age 45 and 65 for both Men and Women, 2020 (In %age)
North America Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
North America Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Market Opportunity Chart of North America Alzheimer Drugs Market- By Country, By Value (Year 2017-2027)
North America Alzheimer Drugs Market- By Country Market Share, 2021 & 2027
United States Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
United State Number of People Living with Alzheimer's Disease, By Age (In Millions),

2020
Alzheimer's disease mortality rate in the United States from 2015 to 2019, (per 100,000 population)
United State Prevalence of Neurological Disorders, 2015-2019 (In Millions)
United States Percentage Changes in Selected Causes of Death (All Ages) Between 2000 and 2019, (In %age)
United State Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
United State Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
United States Population aged 65 and above (% of total Population), 2016-2020
United State Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
United State Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Canada Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
Canada Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Canada Death Rate for Alzheimer Disease (Per 100,000 Population), 2015-2019
Canada Population aged 65 and above (% of total Population), 2016-2020
Canada Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Canada Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Europe Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
Europe Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
European Countries Population ages 65 and above (% of total Population), 2020
Europe Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Europe Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Figure 48: Market Opportunity Chart of Europe Alzheimer Drugs Market- By Country, By Value (Year 2017-2027)
Europe Alzheimer Drugs Market- By Country Market Share, 2020 & 2026
Germany Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
Germany Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Germany Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Germany Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
United Kingdom Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Millions)

United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
United Kingdom Population ages 65 and above (% of total Population), 2016-20
United Kingdom Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
United Kingdom Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
France Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
France Prevalence of Neurological Disorders, 2015-2019 (In Millions)
France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
France Population ages 65 and above (% of total Population), 2016-20
France Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
France Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Italy Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
Italy Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Italy Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Italy Population ages 65 and above (% of total Population), 2016-20
Italy Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Italy Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Asia Pacific Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020
Asia Pacific Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Asia Pacific Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Market Opportunity Chart of APAC Alzheimer Drugs Market- By Country, By Value (Year-2026)
APAC Alzheimer Drugs Market- By Country Market Share, 2021 & 2027
China Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
China Prevalence of Neurological Disorders, 2015-2019 (In Millions)
China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
China Population ages 65 and above (% of total Population), 2016-20
China Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
China Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Japan Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)

Japan Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Japan Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Japan Alzheimer's Drugs company market share (%), 2020
Japan Alzheimer's Drugs company market share (%), 2020
Japan Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Japan Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
India Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
India Prevalence of Neurological Disorders, 2015-2019 (In Millions)
e-pharmacy market in India (USD million)
India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
India Population ages 65 and above (% of total Population), 2016-20
India Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
India Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Australia Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
Australia current health expenditure (% of GDP), (2014-2018)
Australia population aged 65 and above (% of total population), 2017-2021
Australia urban population (% of total population), 2017-2021
Australia Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Australia Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Market Attractiveness Chart of Global Alzheimer Drugs Market- By Drug Class (Year-2017-2027)
Market Attractiveness Chart of Global Alzheimer Drugs Market- By Distribution Channel (Year 2017-2027)
Market Attractiveness Chart of Global Alzheimer Drugs Market- By Region (Year 2017-2027)
Global Alzheimer's Drugs company market share (%), 2020
AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020
AbbVie Inc. Net Income (USD Million), 2016-2020
AbbVie Inc. Sales Revenue Split, By Business Segment (%), FY2020
AbbVie Inc. Sales Revenue Split, By Geography Segment (%), FY2020
F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)
F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)
F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020
F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020
Novartis Annual Sales Revenue (USD Million), 2016-2020
Novartis Annual Net Income/Loss (USD Million), 2016-2020

Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Biogen Sales Revenues, 2016-2020 (USD Million)
Biogen Net Profit, 2016-2020 (USD Million)
Biogen, By Business Segment (%), FY2020
Biogen, By Geographical Segment (%), FY2020
Pfizer Inc., Annual Sales Revenue (USD Million), 2016-2020
Pfizer Inc., Annual Net Income/Loss (USD Million), 2016-2020
Pfizer Inc., sales Revenue, By Geographical Segment (%), FY2020
Eli Lilly and Company Annual Sales Revenue (USD Million), 2016-2020
Eli Lilly and Company Annual Net Income (USD Million), 2016-2020
Eli Lilly and Company Sales Revenue Split, By Business Segment (USD Million), FY2020
Eli Lilly and Company Sales Revenue Split, By Geography Segment (%), FY2020
Takeda Pharmaceutical Company Limited Sales Revenues, 2016-2020 (USD Million)
Takeda Pharmaceutical Company Limited Net Income, 2016-2020 (USD Million)
Takeda Pharmaceutical Company Limited Sales Revenue Split, By Business Segment (%), FY2020
Takeda Pharmaceutical Company Limited Sales Revenue Split, By Geography Segment (%), FY2020
Novo Nordisk Sales Revenues, 2016-2020 (USD Million)
Novo Nordisk Net Profit, 2016-2020 (USD Million)
Novo Nordisk Sales Revenue Split, By Business Segment (%), FY2020
Novo Nordisk Sales Revenue Split, By Geography Segment (%), FY2020
Daiichi Sankyo Company Ltd. Revenue, 2020-2021 (In USD Million)
Daiichi Sankyo Company Ltd. Sales Revenue Split, By Business Segment (%), FY2020
Daiichi Sankyo Company Ltd. Sales Revenue Split, By Geography Segment (%), FY2020
Eisai Co. Ltd. Revenue, 2019-2020 (In USD Billion)
Eisai Co. Ltd. Revenue by Reporting Segment, FY2020

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Product Pipeline of Leading Alzheimer's Drugs Companies
Product Pipeline of Leading Alzheimer's Drugs Companies
Product Pipeline of Leading Alzheimer's Drugs Companies
Product Pipeline of Leading Alzheimer's Drugs Companies

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Global Alzheimer Drugs Market (2022 Edition) – Analysis By Drug Class (Cholinergic, Memantine, Combined Drugs, Others), Distribution Channel, By Region, By Country: Market Insights, Pipeline and Forecast with Impact of Covid-19 (2022-2027)

Product link: https://marketpublishers.com/r/GCE8690AA056EN.html

Price: US$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GCE8690AA056EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below

+44 20 8123 2220
info@marketpublishers.com

and fax the completed form to +44 20 7900 3970